Millions of individuals worldwide have been treated for diabetes with regular insulin injections for decades. However, ...

Awiqli, the world's first weekly insulin, simplifies diabetes management by reducing daily injections while improving ...

Designed to reduce daily insulin injections to a single weekly dose, the long-acting insulin aims to improve treatment ...

Awiqli offers adults with diabetes fewer injections while maintaining effective blood sugar control through weekly dosing.

One injection a week instead of one every day. Danish drugmaker Novo Nordisk has launched Awiqli, or insulin icodec, in India-the world's first once-weekly bas ...

The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee is scheduled to meet on May 24 to review Novo Nordisk A/S’s (NYSE:NVO) application seeking approval for a once-weekly insulin icodec. In ...

According to CRL, more information regarding the manufacturing process and the type 1 diabetes indication is needed before the review can be completed. The Food and Drug Administration (FDA) has ...

In a 7 to 4 vote, an advisory panel to the US Food and Drug Administration (FDA) determined that the potential benefits of the investigational once-weekly basal insulin analog icodec (Novo Nordisk) ...

Novo Nordisk is set to introduce Awiqli, an innovative once-weekly insulin, in India shortly. This remarkable treatment ...

(RTTNews) - Novo Nordisk said that the US Food and Drug Administration has issued a Complete Response Letter or CRL covering the Biologics License Application for once-weekly basal insulin icodec for ...